View
52
Download
0
Category
Tags:
Preview:
DESCRIPTION
CREB & The Development Of Novel Memory Enhancers. Tim Tully Chief Science Officer Dart Neuroscience LLC. 0. 1. 2. 3. 4. 5. 6. 7. Long-Term Memory In The Fruit Fly. 100. 80. 60. PERFORMANCE INDEX. 10x spaced. 40. 10x massed. 20. 1x. 0. RETENTION TIME (day). - PowerPoint PPT Presentation
Citation preview
CREB & The DevelopmentOf Novel Memory Enhancers
Tim TullyChief Science Officer
Dart Neuroscience LLC
765432100
20
40
60
80
100
10x spaced
10x massed1x
RETENTION TIME (day)
PER
FO
RM
AN
CE
IN
DEX
Long-Term MemoryIn The Fruit Fly
Tully et al (1994)
PER
FO
RM
AN
CE I
ND
EX
TIME (days)
hs-dCREB2-rmassed
spaced
0
20
40
60
80
100
-20
1 3 5 7
CREB RepressorBlocks LTM
Yin et al (1994)
See also: Bourtchouladze et al (1994)
0
10
20
30
40
50 control
CREB-a
1x 10x spaced
7-D
AY
MEM
OR
Y
TRAINING SESSIONS
CREB ActivatorEnhances Memory
Yin etal. (1995)
dCREB2 Homologs
Olson etal (2005)
GENESEER
Drug ScreenFor Enhancers of CREB
ATP
cAMP
AMP
AC
PDE PKA
Ca/CaM
CRE
CREB luciferase
nucleus
forskolin
neuroblastoma cell
HT-0712
0
10
20
30
40
50
60
Mem
ory
Score
Vehicle
0.1mg/kg HT0712(60’ after)
*
8 8 8 8
Memory EnhancementIn Normal, Young Mice
2 Trials 5 Trials
Paired-Associate MemoryIn Elderly Macaque
0
5
10
15
20
25
30
vehicle
Tra
inin
g D
ays
to C
rite
rion
1 mg/kg 10 mg/kg 100 mg/kg
Mouse Model Of Rubinstein-Taybi Syndrome
wild-type (sib) CBP+/- mice
Oike etal (1999)
15-min Training
Facilitation Of LTMIn RTS Model
Vehicle HT0712(0.1 mg/kg)
*
wt
CBP+/ -
80
70
60
50
40
30
20
10
0
-10
Mem
ory
Score
Bourtchouladze etal (2003)
Facilitation Of RehabilitationAfter Stroke
Post
-str
oke
moto
r re
covery
Day
0
0.5
1.0
1.5
0 1 2 3 4 5 6 7 8 9 10 11
vehicle
HT-0712(0.15 mg/kg )
MacDonald et al. (2007) Neurorehabil. Neural Repair 6: 486.
Cognitive RehabilitationAfter Traumatic Brain Injury
Hallam etal (2010) unpublished.
Cognitive RehabGeneralizes
Hallam etal (2010) unpublished.
Clinical Safety
Phase 1 (single rising dose)• 42 healthy young and elderly exposed (405 mg max dose)• no serious adverse events
Phase 1 (repeat dose)• 24 healthy young and elderly exposed (135 mg max dose)• no serious adverse events
Phase 1 (interaction with warfarin)
• 21 elderly exposed (45 mg dose)
• no serious adverse events
Phase 2a (28 daily doses)• 55 elderly with AAMI (90 mg max dose)• no serious adverse events
Project ResearchPre-
ClinicalPhase I Phase II Phase III
PDE4
GalR3
MAO-B
GABA-A
Novel
GLYT1
Drug Development Pipeline
HT-2157
BackUp
Back-ups
HT-1067
BackUp
Back-ups
Hits
Screening
HT-4313
HT-0712
Screening
Hits
Acknowlegements
Ken Johns CEOPhil Perera CMOAnne Danks Director, Preclinical DevelopmentAlan Kaplan Director, ChemistryTim Tully Founder, x-CSO
Lila Davachi NYUEmmanuel DeCamp TJUJeff Kleim UF-Gainesville
Collaborators
HT-0712 FacilitatesMotor Rehab After TBI
Hallam etal (2010) unpublished.
HT-0712 FacilitatesCognitive Rehab After TBI
Hallam etal (2010) unpublished.
Drug AloneDoes Not Facilitate
Hallam etal (2010) unpublished.
MEM
OR
Y R
ETEN
TIO
N
0 1 3 5 24TIME (hr)
STM
MTM
ARM LTM
observed
No Measures Of Long-Term MemoryIn The Clinic…
clinical measures of dementia
0 15 45 60 90-30-20-100
7d - 7hrDose (mg)
P = 0.22P = 0.03P = 0.32P = 0.20
7-Day WordRecallIn Humans With AAMI
Recommended